Giá hiện tại
Giá mục tiêu
Third Harmonic Bio Inc. is an innovative biotechnology company dedicated to advancing breakthrough therapies for severe immunological and inflammatory disorders. Utilizing its proprietary genetic engineering platform, th...|
e.g. Promoter holding
Loading chart...
Dự báo EPS và doanh thu theo đồng thuận của các nhà phân tích.
| Metric (B) | FY 2024 | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 | FY 2025 | FY 2025 | FY 2026 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.31 | $-0.27 | $-0.30 | $-0.33 | $-0.30 | $-0.23 | $-0.18 | $-0.92 | $-0.94 | $-0.94 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| +0.0% | +0.0% | +0.0% | +10.8% | +11.8% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DBright Min... | DRUG | $227.96M | — | 1.05 | — | — | -13.60% | — |
| 2. | RRocket Pha... | RCKT | $256.82M | — | 0.78 | — | — | -5.04% | — |
| 3. | LLexeo Ther... | LXEO | $235.59M | — | 1.00 | — | — | -46.80% | — |
| 4. | IImmuneerin... | IMRX | $240.27M | — | 1.42 | — | — | -33.50% | -99.80% |
| 5. | SAcelyrin I... | SLRN | $229.17M | — | 0.56 | — | — | -51.10% | — |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Quarter (M) | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0.84 | 0 | 0 | 0 | 0.05 | 0 |
COGS | 0.17 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 |
Gross Profit | -0.17 | -0.18 | 0.82 | -0.01 | -0.01 | -0.01 | 0.02 | -0.01 |
Gross Profit % | - | - | 98.44% | - | - | - | 50% | - |
| 10.71 | 10.85 | 10.39 | 11.28 | 14.06 | 17.07 | 16.44 | 18.72 | |
EBIT | -10.71 | 10.85 | -10.4 | -11.29 | -14.07 | -17.07 | -16.44 | -18.72 |
OPM % | - | - | -1244.62% | - | - | - | -34247.92% | - |
Non-Operating Income | 3.15 | -3.5 | 3.57 | 3.43 | 3.36 | 3.27 | 3.33 | 2.88 |
PBT | -7.56 | 7.34 | -6.84 | -7.86 | -10.71 | -13.8 | -13.11 | -15.83 |
Income Tax | -3.16 | -0.01 | 0.27 | -0.03 | 0 | 0 | 0 | 0 |
Tax Rate % | 41.77% | -0.16% | -3.91% | 0.4% | - | - | - | - |
Net Income | -7.56 | 7.34 | -6.84 | -7.86 | -10.71 | -13.8 | -13.11 | -15.83 |
NPM % | - | - | -817.7% | - | - | - | -27306.25% | - |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0.04 | 0.04 | 0.05 |
Gross Profit | 0 | 0 | -0.04 | -0.04 | -0.05 |
Gross Profit % | - | - | - | - | - |
| 11.12 | 19 | 37.71 | 43.92 | 58.87 | |
EBIT | -11.12 | -19 | -37.71 | -43.95 | 58.87 |
OPM % | - | - | - | - | - |
Non-Operating Income | -1.69 | -10.61 | 2.55 | 13.13 | -13.4 |
PBT | -12.81 | -29.61 | -35.16 | -30.82 | 45.47 |
Income Tax | -0 | 10.61 | 2.55 | 0 | 45.47 |
Tax Rate % | 0.01% | -35.82% | -7.26% | - | 100% |
Net Income | -12.81 | -29.61 | -37.71 | -30.82 | 45.47 |
NPM % | - | - | - | - | - |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| 8.28 | 128.28 | 288.88 | 269.07 | 285.06 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.16 | 0.88 | 3.96 | 3.38 | 5.47 | |
| 0 | 0 | 5.84 | 5.26 | 4.07 | |
Total Assets | 8.43 | 129.16 | 298.68 | 277.71 | 294.61 |
| 0 | 0 | 0 | 0 | 0.01 | |
| 0.34 | 123.48 | 289.06 | 269.08 | 285.14 | |
| 0 | 0 | 4.34 | 3.95 | 3.21 | |
| 2.21 | 5.69 | 4.88 | 3.93 | 5.39 | |
| 24.58 | 170.18 | 0.39 | 0.74 | 0.86 | |
Total Liabilities | 27.13 | 299.35 | 298.68 | 277.71 | 294.61 |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| -9.19 | -15.75 | -34.92 | -20.43 | -34.5 | |
| -0.04 | -0.04 | -0.04 | -0.17 | -0.01 | |
| 10.82 | 135.75 | 195.99 | 0.8 | 50.51 | |
Net CFNet Cash Flow | 1.6 | 119.97 | 161.04 | -19.8 | 15.99 |
FCFFree Cash Flow | -9.22 | -15.78 | -34.95 | -20.59 | -34.51 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| - | -47.8% | -18.3% | -11.0% | 16.4% | |
| - | - | 0.02 | 0.01 | 0.01 | |
| 3.81 | 22.72 | 51.80 | 50.29 | 40.87 | |
| - | 0.00 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | 0.72 | 0.53 | 0.93 | 0.66 | -0.76 |
Payout Ratio | - | - | - | - | - |
| - | - | - | - | - | |
| -1.57 | -7.07 | -1.69 | -0.77 | 1.01 | |
| - | - | -2.55 | -14.09 | 10.90 | |
| 3.00 | 5.00 | 4.00 | 4.00 | 3.00 | |
| - | - | - | - | - | |
| 0.00 | 0.00 | 50.00 | 50.00 | 60.00 | |
| - | - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Ai sở hữu Third Harmonic Bio Inc, theo hồ sơ SEC
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| Shares held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 5.8M | 12.4M | 12.4M | 12.4M | 11.2M | 11.2M | 11.2M | 11.2M | 0 | |
ForeignForeign institutions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
USUS institutions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Govt.Government & pensions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Partnership | DE | 3,724,167 | 8.20% | SC 13G · 14 Feb 2025 | |
| Investment adviser | MA | 0 | 0.00% | SC 13G/A · 14 Nov 2025 | |
| Investment adviser | DE | 0 | 0.00% | SC 13G/A · 15 May 2025 | |
| Holding company | DE | 1,066 | 0.00% | SC 13G/A · 12 May 2025 | |
| Partnership | DE | 0 | 0.00% | SC 13G/A · 16 Apr 2025 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 15 Jul 2025 | 1,421,567 | -4.0% | 9.48 | |
| 30 Jun 2025 | 1,480,598 | +3.9% | 5.79 | |
| 13 Jun 2025 | 1,425,686 | -6.4% | 5.13 | |
| 30 May 2025 | 1,523,148 | -0.9% | 5.41 | |
| 15 May 2025 | 1,537,621 | -8.1% | 4.59 | |
| 30 Apr 2025 | 1,672,516 | -2.5% | 3.93 | |
| 15 Apr 2025 | 1,715,830 | 0.0% | 1.02 | |
| 31 Mar 2025 | 1,715,365 | +11.7% | 5.17 | |
| 14 Mar 2025 | 1,535,429 | -5.3% | 4.34 | |
| 28 Feb 2025 | 1,622,050 | -55.7% | 4.13 | |
| 14 Feb 2025 | 3,661,008 | +2.6% | 1.80 | |
| 31 Jan 2025 | 3,569,036 | +1.4% | 15.15 | |
| 15 Jan 2025 | 3,521,408 | -1.9% | 11.19 | |
| 31 Dec 2024 | 3,590,117 | +7.1% | 19.37 | |
| 13 Dec 2024 | 3,351,019 | +9.6% | 17.23 | |
| 29 Nov 2024 | 3,056,584 | -2.5% | 9.71 | |
| 15 Nov 2024 | 3,133,499 | +8.9% | 14.52 | |
| 31 Oct 2024 | 2,876,298 | +3.3% | 20.02 | |
| 15 Oct 2024 | 2,784,276 | +26.2% | 20.94 | |
| 30 Sep 2024 | 2,205,532 | +17.5% | 4.16 | |
| 13 Sep 2024 | 1,877,440 | +0.9% | 28.20 | |
| 30 Aug 2024 | 1,860,557 | +4.3% | 31.79 | |
| 15 Aug 2024 | 1,783,249 | +4.1% | 25.07 | |
| 31 Jul 2024 | 1,712,712 | +8.3% | 24.63 |
FINRA consolidated short interest, reported twice a month for every US listing.
Hồ sơ SEC và bản ghi cuộc gọi kết quả kinh doanh của Third Harmonic Bio Inc
What recent news says about Third Harmonic Bio Inc, scored for sentiment.